Alliance Global Partners lowered the firm’s price target on Journey Medical (DERM) to $10.50 from $11 and keeps a Buy rating on the shares. Journey Medical’s Q4 earnings results were at the lower end of the firm’s expectations, the analyst tells investors in a research note. The firm is targeting 2025 as an inflection year given the launch of the rosacea treatment Emrosi.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DERM:
- Journey Medical Corporation Reports 2024 Financial Results
- Journey Medical reports FY24 EPS (72c) vs (21c) last year
- Journey Medical launches Emrosi for the treatment of rosacea
- Journey Medical Corporation (DERM) Q4 Earnings Cheat Sheet
- Journey Medical announces results from MVOR-1, MVOR-2 trials published